Alterations in neuropeptide mRNA expression in the striatum in Parkinson's disease

2002

GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets

2001

Parkinson's disease (PD) is associated with a progressive loss of dopamine neurons in the substantia nigra and degeneration of dopaminergic terminals in the striatum. Although L-DOPA treatment provides the most effective symptomatic relief for PD it does not prevent the progression of the disease, and its long-term use is associated with the onset of dyskinesia. In rodent and primate studies, glial cell line-derived neurotrophic factor (GDNF) may prevent 6-OHDA- or MPTP-induced nigral degeneration and so may be beneficial in the treatment of PD. In this study, we investigate the effects of GDNF on the expression of dyskinesia in L-DOPA-primed MPTP-treated common marmosets, exhibiting dyskin…

Secretogranin II mRNA expression is increased in Parkinson disease and in MPTP-treated marmosets exposed to chronic L-Dopa administration

2001

Neuropeptide Y: una overview sugli effetti di neuro- ed immuno-modulazione

2002